Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone
Open Access
- 31 March 2016
- journal article
- Published by European Journal of Chemistry in European Journal of Chemistry
- Vol. 7 (1), 19-29
- https://doi.org/10.5155/eurjchem.7.1.19-29.1346
Abstract
Design and synthesis of some new pyridopyrazinone derivatives as anti-proliferative agents is described. The cytotoxic activities of the synthesized compounds against melanoma cell line (LOXIMVI), ovarian cell line (OVCAR3), thyroid cell lines (CAL62, FTC133, BCPAP and ML1) and colon cell lines (HT29 and HCT116) were investigated. Results revealed that most compounds were active and compound 3d was the most active one. It exhibited promising activity against all tested cell lines. In addition, in vitro kinase assay against both WTBRAF and V600EBRAF was performed for all synthesized compounds. Furthermore, molecular docking of tested compounds was established with active site of V600EBRAF kinase domain. Results of kinase inhibition assay and molecular docking revealed that, compounds 1, 3d, e, h, i, 5d, e and 6b were potent inhibitors for V600EBRAF kinase enzyme involved in number of cancer types as melanoma, ovarian and thyroid cancer. The newly synthesized pyridopyrazinones substituted with different substituents at C-3 or fused with triazine heterocycle at C-3 and C-4 afforded potent V600EBRAF inhibitors and exhibited promising cytotoxic activities against different cancer types such as melanoma, ovarian, thyroid and colon cancer.Keywords
This publication has 29 references indexed in Scilit:
- Ras/Raf/MEK InhibitorsPublished by Springer Science and Business Media LLC ,2007
- Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroidCancer, 2007
- Back to the roots: the remarkable RAF oncogene storyCellular and Molecular Life Sciences, 2006
- Targeting the mitogen-activated protein kinase cascade to treat cancerNature Reviews Cancer, 2004
- Guilty as charged: B-RAF is a human oncogeneCancer Cell, 2004
- Switching on kinases: oncogenic activation of BRAF and the PDGFR familyNature Reviews Cancer, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- BRAF Mutation in Papillary Thyroid CarcinomaJNCI Journal of the National Cancer Institute, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Quantitative Structure-Activity Relationship Studies on Anticancer DrugsChemical Reviews, 1994